Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-16
2011-10-18
Stoica, Elly-Gerald (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001500, C530S324000
Reexamination Certificate
active
08039429
ABSTRACT:
The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR-CXC chemokine receptor agonists and antagonists.
REFERENCES:
patent: 5840524 (1998-11-01), Van Damme
patent: 2007/0021593 (2007-01-01), Gordon et al.
patent: WO02/070565 (2002-12-01), None
Clark-Lewis I et al: “Structural Requirements for Interleukin-8 Function Identified by Design of Analogs and CXC Chemokine Hybrids” Journal of Biological Chemistry, American Society of Biolochemical Biologists, Birmingham, US, vol. 269, No. 23, Jun. 10, 1994, pp. 16075-16081, XP001030753 ISSN: 0021-9258.
Li Fang et al: “IL-8(3-73)k11r Is a High Affinity Agonist of the Neutrophil CXCR1 and CXCR2” Biochemical and Biophysical Research Communications, col. 286, No. 3, Aug. 24, 2001, pp. 595-600, SP002551480 ISSN: 0006-291X.
Zhao et al: “humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8(3-74)K11R/G31P, effectively block ELR-CXC Chemokine activity and airway endotoxemia pathology” International Immunopharmacology, Elsevier, Amsterdam, NL, vol. 7, No. 13, Nov. 6, 2007, pp. 1723-1731, XP022332230.
Gordon, J.R. et al “The Combined, CXCR1/CXCR2 Antagonist CXCL8(3-74) K11R/G31 Blocks Neutrophil Infiltration, Pyrexia, and Pulmonary Vascular Pathology in Endotoxemic Animals”, Dec. 2005, J. Leukoc Biol., vol. 78(6) pp. 1265-1272 ISSN 0741-5400 entire document.
Li, F. et al CXCL8 (3-73) K11R/G31P Antagonizes the Neutrophil Chemoattractants Present in Pasteurellosis and mastitits Lesions and Abrogates Neutrophil Influx into Intradermal Endotoxin Challenge Sites in Vivo, Nov. 2002, Vet. Immunol. Immunopathol. vol. 90 (1-2) pp. 67-77 ISSN 0165-2427 entire document.
Li, F. et al “CXCL8 (3-73) k11r/g31p Antagonzies Ligand Binding to the Neutrophil CXCR1 and CXCR2 Receptors and Cellular Respolnses to CXCL8/IL-8” May 2002 Biochem, Biophys. Res. Comm. vol. 293(3) pp. 939-944 ISSN 0006-291X entire document.
Ade & Company Inc.
Stoica Elly-Gerald
University of Saskatchewan
Williams Michael R.
LandOfFree
Method of treatment using high-affinity antagonists of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment using high-affinity antagonists of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment using high-affinity antagonists of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301948